dyslipidemia
DYSLIPIDEMIA
Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.

Definition

  • An abnormality in lipoprotein metabolism that results in elevations of low density lipoprotein-cholesterol(LDL-C), total cholesterol (TC), triglycerides (TG), and/or non-high-density lipoprotein-cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein-cholesterol (HDL-C) levels
  • Increase in serum concentration of TC, LDL, TG or non-HDL-C are equivalent to increased risk for cardiovascular diseases

Etiology

  • Depends on the type of dyslipidemia
  • Hereditary disorders associated with dyslipidemia include familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
  • Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
2 years ago
Based on a population-based cohort study, pregnant women who underwent assisted reproductive technology, particularly following cryopreservation, are at greater risk for hypertensive disorders.
Christina Lau, 3 years ago

The novel oral anticoagulant (OAC) dabigatran is better than warfarin for stroke prevention in Asian patients with atrial fibrillation (AF), according to a new analysis that included patients from Hong Kong.

one year ago
During the Diabetes Asia 2015 Conference, Professor Jean Claude Mbanya discussed the role of sulphonylureas in today’s management of type 2 diabetes (T2D). Important points from his presentation are summarized below.
one year ago
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors.